ADVERTISEMENT

Covid-19 Special Report - Race To The Finish Line: SBI Research

Covid-19 Special Report - Race To The Finish Line: SBI Research

<div class="paragraphs"><p>People wait in line for a dose of Covid-19 vaccine at the heath center in the village of Bazrak, Uttar Pradesh, India. (Photographer: Anindito Mukherjee/Bloomberg)</p></div>
People wait in line for a dose of Covid-19 vaccine at the heath center in the village of Bazrak, Uttar Pradesh, India. (Photographer: Anindito Mukherjee/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

SBI Research Report

In India, we have 51 cases of Delta Plus variant in 12 states by end-June.

New cases in top 15 districts, which are mostly urban increased again in June. But the good thing is that their fatality rate has been constant for 3 months.

However, the share of rural districts in new cases has refused to decline meaningfully since July 2020, when it breached 45% and has vacillated since then. Vaccination seems to be the only answer.

Global data shows that on an average third wave peak cases are around 1.7 times the peak cases at the time of second wave.

India has achieved its second wave peak on May 7 and going by the current data, India can experience cases around 10,000 somewhere around 2nd week of July. However, the cases can start rising by second fortnight of August!

Click on the attachment to read the full report:

SBI Covid Special Report July 5.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.